ABSTRACT
MMP-9 is a zinc-dependent endopeptidase that is involved in the proteolytic degradation of the extracellular matrix and plays an important role in cancer migration, invasion, and metastasis. The aim of this study was to evaluate the potential of MMP-tracers [18 F]BR420 and [18 F]BR351 for MMP-9 imaging in a colorectal cancer xenograft model. [18 F]BR420 and [18 F]BR351 were synthesized using an automated synthesis module. For [18 F]BR420, a novel and improved radiosynthesis was developed. Plasma stability and MMP-9-targeting capacity of both radiotracers was compared in the Colo205 colorectal cancer model. MMP-9 and MMP-2 expression levels in the tumors were evaluated by immunohistochemistry and in situ zymography. µPET imaging as well as ex vivo biodistribution revealed a higher tumor uptake for [18 F]BR420 (3.15% ± 0.03% ID/g vs 0.94% ± 0.18% ID/g for [18 F]BR351 at 2 hours pi) but slower blood clearance compared with [18 F]BR351. [18 F]BR351 was quickly metabolized in plasma with 20.28% ± 5.41% of intact tracer remaining at 15 minutes postinjection (PI). By contrast, [18 F]BR420 displayed a higher metabolic stability with >86% intact tracer remaining at 2 hours PI. Immunohistochemistry revealed the presence of MMP-9 and MMP-2 in the tumor tissue, which was confirmed by in situ zymography. However, an autoradiography analysis of tracer distribution in the tumors did not correlate with MMP-9 expression. [18 F]BR420 displayed a higher tumor uptake and higher stability compared with [18 F]BR351 but a low tumor-to-blood ratio and discrepancy between tracer distribution and MMP-9 immunohistochemistry. Therefore, both tracers will not be usefulness for MMP-9 imaging in colorectal cancer.
Subject(s)
Colorectal Neoplasms/diagnostic imaging , Matrix Metalloproteinase 9/metabolism , Pyrimidinones/chemical synthesis , Radiopharmaceuticals/pharmacokinetics , Sulfonamides/chemical synthesis , Valine/analogs & derivatives , Animals , Cell Line, Tumor , Female , Fluorine Radioisotopes/chemistry , Humans , Metabolic Clearance Rate , Mice , Mice, Nude , Positron Emission Tomography Computed Tomography , Pyrimidinones/pharmacokinetics , Radiopharmaceuticals/adverse effects , Radiopharmaceuticals/chemical synthesis , Sulfonamides/pharmacokinetics , Tissue Distribution , Valine/chemical synthesis , Valine/pharmacokineticsABSTRACT
INTRODUCTION: Phosphodiesterase 7 (PDE7) hydrolyzes selectively cyclic adenosine monophosphate (cAMP) which is an intracellular second messenger. PDE7 is expressed by 2 genes which are both present in the brain. To date there is no radiotracer for PDE7 imaging described and detection of PDE7 has only been performed by ex vivo techniques. In this report we describe the radiosynthesis of a novel fluorine-18 labeled radiotracer for PDE7 as well as the in vivo evaluation in mice to verify whether it has potential for imaging of PDE7 in the brain. METHODS: We have synthesized a potent fluorinated PDE7 inhibitor, [(18)F]MICA-003 (PDE7 IC(50)=17 nM) and the corresponding tosylate precursor for radiolabeling. [(18)F]MICA-003 was injected in C57BL/6J mice (n=5) and in vivo images were acquired by µPET imaging. Radiometabolite analysis in plasma and brain was performed to determine the stability of the radioligand. RESULTS: [(18)F]MICA-003 was synthesized by direct fluorination of the tosylate and produced in high decay corrected radiochemical yield (40%), high radiochemical purity (>98%) and high specific activity (86-497 GBq/µmol). µPET imaging revealed that [(18)F]MICA-003 crosses the blood brain barrier and has a homogenous distribution over the brain which washes out after the initial peak uptake. [(18)F]MICA-003 was quickly metabolized in plasma with 8.9%±0.59% of intact [(18)F]MICA-003 remaining at 5m in post injection. We observed the formation of three distinct radiometabolites of which the main radiometabolite was also detected in the brain in a proportion of 25.7±2.57% at this same time point. CONCLUSION: We have described the synthesis and in vivo evaluation of a novel radioligand for PDE7 imaging. Despite high uptake in the brain and favorable kinetics in vivo, the presence of a brain penetrant radiometabolite makes [(18)F]MICA-003 unfavorable for the accurate quantification of PDE7 and more stable spiroquinazolinones analogs are in development.
Subject(s)
Brain/diagnostic imaging , Cyclic Nucleotide Phosphodiesterases, Type 7/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Fluorine Radioisotopes/pharmacokinetics , Neuroimaging/methods , Positron-Emission Tomography/methods , Radiopharmaceuticals/pharmacokinetics , Animals , Brain/enzymology , Enzyme Inhibitors/chemistry , Male , Mice , Mice, Inbred C57BL , Radiochemistry , Spiro Compounds/chemistry , Tissue DistributionABSTRACT
Currently, there are about 20 antiepileptic drugs on market. Still, seizures in about 30% of patients with epilepsy are not adequately controlled, or the drugs cause quality-of-life-compromising adverse events. Importantly, there are no treatments to combat epileptogenesis, a process that leads to the development of epilepsy and its progression. To fill the gaps in the treatment of epilepsy, there is an urgent need for identification of novel treatment targets. Data emerging over the recent years have shown that different components of the extracellular matrix (ECM) contribute to many components of tissue reorganization during epileptogenesis and the ECM is also a major regulator of synaptic excitability. Here, we review the role of urokinase-type plasminogen activator receptor interactome, matrix metalloproteinases, tenascin-R, and LGI1 in epileptogenesis and ictogenesis. Moreover, the role of the ECM in epilepsy-related comorbidities is reviewed. As there is active development of new imaging methods, we also summarize the data available on imaging of the ECM in epilepsy.
Subject(s)
Epilepsy/pathology , Extracellular Matrix/physiology , Receptors, Urokinase Plasminogen Activator/metabolism , Animals , Anticonvulsants/therapeutic use , Epilepsy/drug therapy , Epilepsy/metabolism , Extracellular Matrix/drug effects , Humans , Receptors, Urokinase Plasminogen Activator/drug effectsABSTRACT
Boron clusters, and especially dicarba-closo-dodecaboranes, can be used as hydrophobic pharmacophores in the design of new drugs and radiotracers because of their hydrophobic character, spherical structure, and excellent chemical and photochemical stability. In the present paper, the synthesis and in vivo evaluation of (11) C-labeled (1,7-dicarba-closo-dodecaboran-1-yl)-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}amide, an analog of the D2 receptor ligand [(11) C]raclopride, is described. The radiosynthesis was approached by reaction of the demethylated precursor with [(11) C]CH3 I in basic media; moderate radiochemical yields (18.2 ± 2.8%, decay corrected), and excellent radiochemical purities (>98%) were obtained in overall synthesis time of ~50 min. In vivo assays showed a biodistribution pattern with significant uptake in liver, kidneys and lungs at short times (t = 4 min) after administration and increasing accumulation in bladder at longer times (t ≥ 14.5 min). Although brain positron emission tomography scans showed good blood brain barrier penetration, the high unspecific uptake observed in different brain regions impedes its applicability as D2 receptor ligand.
Subject(s)
Amides/chemical synthesis , Boron Compounds/chemical synthesis , Pyrrolidines/chemical synthesis , Amides/pharmacokinetics , Animals , Boron Compounds/pharmacokinetics , Carbon Radioisotopes , Chemistry Techniques, Synthetic , Male , Positron-Emission Tomography , Pyrrolidines/pharmacokinetics , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D2/metabolismABSTRACT
A novel ester type linker which upon cleavage releases the glycans as carbamate protected aminoglycosides was successfully employed in the sequential assembly of L-idose and azido glucose monosaccharide building blocks to heparan sulfate precursors.